Myriad Genetics Inc

Healthcare · Diagnostics & Research

4.00$ -0.2% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

Myriad Genetics Inc (MYGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 707 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet MYGN
Line item	1995	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	80	76	67	54	106	172	157	183	188	159	277	376	499	466	594	611	691	804	824	766	881	1,209	1,175	1,563	1,419	1,321	1,199	1,147	1,028	707
Current Assets	51	49	32	14	86	137	85	103	137	136	252	253	377	366	474	418	422	484	322	284	315	302	328	349	389	485	275	314	298	333
Cash	13	16	15	5.4	56	36	61	62	84	50	99	143	238	64	93	53	86	104	65	64	69	102	111	93	117	257	57	132	102	150
Cash & Short-Term Investments	13	16	15	9.9	81	127	73	73	115	114	228	214	329	317	403	346	341	372	186	145	159	151	181	137	151	339	115	141	102	150
Receivables	–	0.5	0.6	3.2	2.8	5.8	7.5	22	15	18	22	32	45	45	48	51	63	97	85	88	95	96	103	139	90	91	102	114	121	115
Inventory	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-399	8.2	12	5.0	24	25	38	42	34	31	27	15	20	22	28	31
Goodwill	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	56	57	57	169	177	195	316	319	417	329	239	287	287	286	52
Intangible Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.1	17	16	13	205	193	228	492	455	685	579	404	380	350	262	153
Total Liabilities	9.4	9.9	9.9	5.4	29	33	29	19	15	23	27	35	74	32	36	44	55	75	105	104	132	441	209	474	538	353	313	363	327	339
Current Liabilities	9.0	9.8	9.9	5.3	29	33	29	19	15	23	27	35	74	32	27	34	45	65	81	69	72	218	102	118	146	204	137	156	164	134
Short-Term Debt	0.3	0.3	0.1	–	–	–	3.6	–	–	–	–	–	–	–	–	9.6	–	–	–	–	–	66	68	79	14	13	14	16	13	6.9
Accounts Payable	2.2	2.6	5.1	2.9	4.3	9.7	9.5	11	7.9	12	12	16	25	14	8.9	11	10	18	23	21	21	22	26	33	21	30	29	26	32	30
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	224	–	–	–	39	40	120
Shareholders' Equity	70	66	58	48	78	140	129	163	173	136	250	340	426	434	558	567	636	729	719	662	748	768	966	1,089	881	968	886	783	701	368
Retained Earnings	-15	-24	-34	-44	-53	-60	-74	-99	-139	-179	-217	-252	-205	-120	-10	-39	-13	31	2.0	-77	-73	-78	54	26	-227	-254	-366	-630	-757	-1,123
Shares Outstanding	30	36	37	38	40	46	47	51	55	61	73	82	93	99	99	92	86	83	78	75	73	69	72	76	75	78	81	83	91	93

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings